Rebecca Miksad, MD, MPH

Oncology

Doctor Rebecca A. Miksad, MD works in the field of Oncology. She researched medicine at Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18 in research and 49 in primary care medicine She has 1 awards "Meaningful Use Stage 1 Certification". Rebecca Miksad has written publications. She has 30 publications published with PubMed. The lastest publication is: 'Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier.' Dr. Rebecca A. Miksad accepts Medicare payments and is registered with Medicare.gov.

Publications

---

• Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatoCellular carcinoma.
• A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatoCellular carcinoma patients in a Western institution.
• Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors.
• When a Decision Must Be Made: Role of Computer Modeling in Clinical Cancer Research.
• Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease.
• Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.
• Measuring the quality-of-life effects of diagnostic and screening tests.
• Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung Cancer.
• Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular Cancer.
• Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic Cancer translate into clinical significance and value?
• Prostate Cancer in a transgender woman 41 years after initiation of feminization.
• Case of fatal sickle Cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient.
• From treatment to prevention: the interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa.
• Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar CholangioCarcinoma.
• Hepatic hydrothorax associated with vitamin a toxicity.
• What is the role of adjuvant therapy after liver transplantation for hepatoCellular carcinoma?
• Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas Cancer.
• Phase 1/2 study of everolimus in advanced hepatoCellular carcinoma.
• Treatment of Cancer pain with noninvasive brain stimulation.
• Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatoCellular carcinoma: a phase II study.
• Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic Cancer.
• Safety of bevacizumab in patients with advanced Cancer: a meta-analysis of randomized controlled trials.
• Exploratory analysis of early toxicity of sunitinib in advanced hepatoCellular carcinoma patients: kinetics and potential biomarker value.
• Evaluation of the SCA instrument for measuring patient satisfaction with Cancer care administered via paper or via the Internet.
• Progression-free survival as a surrogate endpoint in advanced breast Cancer.
• Cost-effectiveness of primarily human papillomavirus-based cervical Cancer screening in settings with currently established Pap screening: a systematic review commissi...
• Detection of prostate Cancer following gender reassignment.
• Methods for measuring temporary health States for cost-utility analyses.
• Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenoCarcinoma classifier.

Schools

---

• Weill Cornell Medical College

• Cornell University

• Meml Sloan Kettering Hospital

• Ny Hospital Cornell

• Beth Israel Deaconess Hospital Beth Israel Med Center

Procedures Preformed

---

• Thoracentesis

Conditions Treated

---

• Acute Leukemia
• Adrenal Gland Cancer
• Anemia
• Basal Cell Carcinoma
• View All

Doctors Specialties

---

• Medical Oncology
• Oncology

Accepted Insurances

---

Awards

---

• Meaningful Use Stage 1 Certification

Education

---

• Harvard Medical School
• Harvard School of Public Health
• Beth Israel Deaconess Medical Center
• New York Presbyterian Hospital
• Weill Cornell Medical College of Cornell University

Hospital

---

• Beth Israel Deaconess Medical Center

Drug Facts

---

NPI NUMBER		1174745103
NPPES Provider LastName		MIKSAD
NPPES Provider FirstName		REBECCA
NPPES Provider ZIPCode		02215
NPPES Provider State		MA
Specialty Description		Internal Medicine
Total Claim Count		49.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1174745103
Last Name Of The Provider	MIKSAD
First Name Of The Provider	REBECCA
View All

Similar Doctors

---

	Dr. Aparna Raj, MD This Doctor is OpenDoctor Recommended.
	Dr. Cesar M. Castro, MD This Doctor is OpenDoctor Recommended.
	Dr. Jonathan Carlson, MD This Doctor is OpenDoctor Recommended.
	Dr. Jane C. Weeks, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. James W. Mier, MD This Doctor is OpenDoctor Recommended.
	Dr. Paula G. Fraenkel, MD This Doctor is OpenDoctor Recommended.
	Dr. John Koreth, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Levi A. Garraway, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Atish D. Choudhury, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard A. Robinson, MD This Doctor is OpenDoctor Recommended.
	Dr. Sara M. Tolaney, MD This Doctor is OpenDoctor Recommended.
	Dr. Brian M. Wolpin, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Geoffrey R. Oxnard, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Steven E. Come, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Robert E. Martell, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog